Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme
Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme
复制标题
DOI：
10.1016/s0140-6736(03)12681-5
复制
发表时间：
2003-03-08
期刊：
影响因子：
168.9
通讯作者：
Royds, JA
中科院分区：
文献类型：
--
作者：
Hakin-Smith, V;Jellinek, DA;Royds, JA
尽管在多形性胶质母细胞瘤的分子发病机制方面取得了进展，但还没有确定可靠的预后标记物。我们分析了77例多形性胶质母细胞瘤的端粒酶活性和端粒长度。19例患者(25%)有端粒替代延长(ALT)表型。此表型患者的中位生存期为542d(95%CI114-970)，端粒正常的多形性胶质母细胞瘤患者的中位生存期为247d(224-270d)(p=0.0003)。考克斯的回归分析表明，这种关联不受年龄的影响。在非ALT肿瘤患者中，端粒酶活性不影响生存期(中位数为287vs236天，p=0.275)。我们得出结论，ALT是多形性胶质母细胞瘤患者的一个预后指标。
Despite advances In the molecular pathogenesis of giloblastoma multiforme, no reliable prognostic markers have been Identified. We analysed telomerase activity and telomere lengths In giloblastoma multiformes from 77 patients. 19 patients (25%) had tumours with the alternative-lengthening-of-telomere (ALT) phenotype. Median survival for patients with this phenotype was 542 days (95% CI 114-970) compared with 247 days (224-270) for glioblastoma multiformes with normal telomeres (p=0.0003). Cox's regression analysis showed that this association is independent of age. In patients with non-ALT tumours, telomerase activity did not affect survival (median 287 [199-375] vs 236 [230-242] days, p=0.275). We conclude that ALT Is a prognostic Indicator for patients with glioblastoma multiforme.